US Patent

US9296724 — Substituted pyridazinecarboxamides as kinase inhibitors

Method of Use · Assigned to Xcovery Holding Co LLC · Expires 2029-06-18 · 3y remaining

Vulnerability score 81/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a class of compounds, specifically substituted pyridazinecarboxamides, as kinase inhibitors for treating disorders related to abnormal protein kinase activities.

USPTO Abstract

Pyridazine derivatives (e.g., Formula I) have unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as cancer.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-4099 — ensartinib-hydrochloride
U-4099 — ensartinib-hydrochloride

Patent Metadata

Patent number
US9296724
Jurisdiction
US
Classification
Method of Use
Expires
2029-06-18
Drug substance claim
Yes
Drug product claim
No
Assignee
Xcovery Holding Co LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.